Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2020-06-23 Transaction in Own Shar…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Transaction in Own Shares Classification · 1% confidence The document explicitly details 'Disclosure of transactions in own shares' over a specific period (15/06/2020 to 19/06/2020) and presents aggregated data on the volume and price of shares acquired by the issuer (IPSEN). This directly corresponds to the definition of a report concerning the company buying back or selling its own shares. The filing type code 'POS' (Transaction in Own Shares) is the most appropriate classification. The document length is short (2638 chars), but it is a detailed report/disclosure itself, not merely an announcement that a report is available, thus overriding the RPA/RNS rule based on content specificity.
2020-06-23 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is a press release from Ipsen dated June 17, 2020, announcing that the FDA granted 'Fast Track' designation for their drug ONIVYDE® in combination therapy for pancreatic cancer. It details clinical trial progress (Phase 1/2 analysis presentation at ESMO, initiation of Phase 3 NAPOLI-3), provides important safety information (Boxed Warnings, Contraindications, Adverse Reactions) typical of a drug label summary, and includes standard corporate boilerplate information about Ipsen. This content structure—a news announcement about regulatory/clinical progress combined with detailed safety/indication information—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/product news. Since it focuses on a specific regulatory/clinical milestone and includes detailed safety information, it is more specific than a general Regulatory Filing (RNS). It is not a full Annual Report (10-K), a Call Transcript (CT), or a dedicated Investor Presentation (IP). Given the focus on a major regulatory event (Fast Track designation) and clinical updates, it aligns best with an Earnings Release (ER) which often includes such operational highlights, or potentially a Regulatory Filing (RNS) if it were purely regulatory, but the format strongly suggests a press release summarizing recent operational achievements. However, looking closely at the definitions, this document is primarily a press release announcing a regulatory achievement (Fast Track designation) and upcoming data presentation. It is not a comprehensive financial report (10-K, IR) nor a brief announcement of a report release (RPA). While ERs often contain operational news, this specific content—a detailed announcement about drug development status and safety profile—is often categorized separately. Since it is a formal announcement of a significant regulatory event and clinical trial status, and it is not a financial report, it fits best under the general 'Regulatory Filings' (RNS) category if a more specific category like 'LTR' (Legal Proceedings Report) or 'CAP' (Capital/Financing Update) does not apply. Since it is not about legal proceedings or financing, and it is a formal announcement, RNS is the most appropriate fallback for a significant, non-financial, non-management-change press release. If we consider the content as a major operational update, ER might be considered, but ER usually focuses on financial results. Given the strong regulatory/clinical focus, RNS is the safest classification for a non-standard announcement.
2020-06-17 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen announcing that the FDA granted Fast Track designation for their drug ONIVYDE® for a specific cancer treatment. It details clinical trial progress (Phase 1/2 final analysis presentation, initiation of Phase 3 NAPOLI-3), provides Important Safety Information (Boxed Warnings, Contraindications, Adverse Reactions), and includes standard corporate boilerplate (About Ipsen, Forward Looking Statement). This content structure—a focused announcement about regulatory/clinical progress, often accompanied by safety/labeling information—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/pipeline news. Since it is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a specific shareholder vote document, and it focuses on key financial/pipeline updates rather than just a brief announcement of a report's publication (RPA), the most fitting category is Earnings Release (ER), as these often contain major pipeline updates alongside financial context, or Regulatory Filings (RNS) as a general announcement. Given the focus on FDA designation and clinical trial updates, it strongly resembles the type of material released around earnings periods or as a major pipeline update. However, since it is a press release announcing a regulatory event (Fast Track designation) and clinical data presentation, and not explicitly tied to quarterly financial results (though it mentions 2019 sales figures in the 'About' section), it fits best under the general category for significant corporate announcements that aren't strictly financial reports or specific regulatory forms. Given the options, 'ER' is often used for major press releases containing significant business updates, but 'RNS' (Regulatory Filings/General Announcement) is a safer fallback for non-standard, yet important, corporate news releases. Since it is a detailed press release announcing a regulatory event and clinical data, and not just a brief notice, I will lean towards ER as it contains substantial business/pipeline information, which often accompanies earnings. If it were purely a regulatory filing notification, RNS would be better. Given the depth of the clinical and safety information, ER is plausible, but RNS covers general significant announcements well. I will select RNS as the most appropriate general category for a detailed press release about a regulatory milestone not explicitly labeled as an earnings report.
2020-06-17 English
Inside Information / Other news releases
Transaction in Own Shares Classification · 1% confidence The document explicitly details 'Disclosure of transactions in own shares' occurring between specific dates (08/06/2020 and 12/06/2020). It provides aggregated daily volume and weighted average price data for these transactions. This directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance), which maps to the filing code POS. The document is a specific disclosure, not a general announcement of a report (RPA) or a miscellaneous filing (RNS).
2020-06-16 English
Informations privilégiées / Autres communiqués
Transaction in Own Shares Classification · 1% confidence The document title is "Déclaration des transactions sur actions propres réalisées du 08/06/2020 au 12/06/2020" (Declaration of transactions on own shares carried out from 08/06/2020 to 12/06/2020). This explicitly details the company's activity regarding buying back or selling its own shares over a specific period, presented in a tabular format showing volume and price. This directly corresponds to the definition for 'Transaction in Own Shares' (Code: POS). The document length is short (2723 chars), but it is a direct report/declaration, not an announcement *about* a report, so RPA/RNS is not the primary fit.
2020-06-16 French
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 1% confidence The document is titled "INFORMATIONS CONCERNANT LA TENUE DE L'ASSEMBLEE GENERALE MIXTE DU 29 MAI 2020" (Information concerning the holding of the Combined General Meeting of May 29, 2020). It explicitly discusses the logistics, location (held behind closed doors due to Covid-19), and voting procedures for the upcoming General Meeting. This content directly relates to the Annual General Meeting (AGM) and the materials surrounding it, such as the notice of meeting and convocation notice. This aligns perfectly with the definition for AGM Information (AGM-R). Although it mentions the publication of the notice of convocation, the primary focus is the information surrounding the meeting itself, making AGM-R a better fit than RPA or RNS.
2020-05-07 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.